FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051219658> ?p ?o ?g. }

• W2051219658 endingPage "232" @default.
• W2051219658 startingPage "223" @default.
• W2051219658 abstract "The present study determined whether late-ischemia/early reperfusion therapy with the β(1)-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS).In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5 min of ischemia to the first 5 min of reperfusion). LV-IS were 48.9 ± 8.9%, 41.5 ± 5.4%, 25.8 ± 7.7% and 16.8 ± 7.3% for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n = 12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p < 0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5%, 13.3%, and 16.8%, respectively, compared with saline (p < 0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22%, 28% and 59%, respectively, compared with saline (n = 6, p < 0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22%, 37% and 60%, respectively, compared with saline (p < 0.01).Late-ischemia/early reperfusion therapy with esmolol + milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway." @default.
• W2051219658 created "2016-06-24" @default.
• W2051219658 creator A5012101139 @default.
• W2051219658 creator A5016774211 @default.
• W2051219658 creator A5033649095 @default.
• W2051219658 creator A5052826320 @default.
• W2051219658 creator A5058471860 @default.
• W2051219658 creator A5066617533 @default.
• W2051219658 creator A5076001000 @default.
• W2051219658 creator A5080591427 @default.
• W2051219658 creator A5085003950 @default.
• W2051219658 creator A5089226196 @default.
• W2051219658 date "2011-05-12" @default.
• W2051219658 modified "2023-10-17" @default.
• W2051219658 title "Heart Protection by Combination Therapy with Esmolol and Milrinone at Late-Ischemia and Early Reperfusion" @default.
• W2051219658 cites W1963838778 @default.
• W2051219658 cites W1968657635 @default.
• W2051219658 cites W1981578013 @default.
• W2051219658 cites W1998401262 @default.
• W2051219658 cites W2010688793 @default.
• W2051219658 cites W2028055119 @default.
• W2051219658 cites W2038540078 @default.
• W2051219658 cites W2039855327 @default.
• W2051219658 cites W2047947808 @default.
• W2051219658 cites W2054620863 @default.
• W2051219658 cites W2057646444 @default.
• W2051219658 cites W2072423902 @default.
• W2051219658 cites W2079253582 @default.
• W2051219658 cites W2087126389 @default.
• W2051219658 cites W2119605294 @default.
• W2051219658 cites W2124791839 @default.
• W2051219658 cites W2124993595 @default.
• W2051219658 cites W2132115642 @default.
• W2051219658 cites W2143762484 @default.
• W2051219658 cites W2147791296 @default.
• W2051219658 cites W2153298328 @default.
• W2051219658 cites W2157932674 @default.
• W2051219658 cites W2168101485 @default.
• W2051219658 cites W2169883929 @default.
• W2051219658 cites W2186118727 @default.
• W2051219658 cites W2312997470 @default.
• W2051219658 doi "https://doi.org/10.1007/s10557-011-6302-z" @default.
• W2051219658 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3110274" @default.
• W2051219658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21562974" @default.
• W2051219658 hasPublicationYear "2011" @default.
• W2051219658 type Work @default.
• W2051219658 sameAs 2051219658 @default.
• W2051219658 citedByCount "24" @default.
• W2051219658 countsByYear W20512196582012 @default.
• W2051219658 countsByYear W20512196582013 @default.
• W2051219658 countsByYear W20512196582014 @default.
• W2051219658 countsByYear W20512196582015 @default.
• W2051219658 countsByYear W20512196582016 @default.
• W2051219658 countsByYear W20512196582017 @default.
• W2051219658 countsByYear W20512196582018 @default.
• W2051219658 countsByYear W20512196582019 @default.
• W2051219658 countsByYear W20512196582020 @default.
• W2051219658 countsByYear W20512196582021 @default.
• W2051219658 countsByYear W20512196582022 @default.
• W2051219658 countsByYear W20512196582023 @default.
• W2051219658 crossrefType "journal-article" @default.
• W2051219658 hasAuthorship W2051219658A5012101139 @default.
• W2051219658 hasAuthorship W2051219658A5016774211 @default.
• W2051219658 hasAuthorship W2051219658A5033649095 @default.
• W2051219658 hasAuthorship W2051219658A5052826320 @default.
• W2051219658 hasAuthorship W2051219658A5058471860 @default.
• W2051219658 hasAuthorship W2051219658A5066617533 @default.
• W2051219658 hasAuthorship W2051219658A5076001000 @default.
• W2051219658 hasAuthorship W2051219658A5080591427 @default.
• W2051219658 hasAuthorship W2051219658A5085003950 @default.
• W2051219658 hasAuthorship W2051219658A5089226196 @default.
• W2051219658 hasBestOaLocation W20512196581 @default.
• W2051219658 hasConcept C126322002 @default.
• W2051219658 hasConcept C164705383 @default.
• W2051219658 hasConcept C178853913 @default.
• W2051219658 hasConcept C2776645727 @default.
• W2051219658 hasConcept C2777953023 @default.
• W2051219658 hasConcept C2780996683 @default.
• W2051219658 hasConcept C42219234 @default.
• W2051219658 hasConcept C71924100 @default.
• W2051219658 hasConcept C84393581 @default.
• W2051219658 hasConcept C98274493 @default.
• W2051219658 hasConceptScore W2051219658C126322002 @default.
• W2051219658 hasConceptScore W2051219658C164705383 @default.
• W2051219658 hasConceptScore W2051219658C178853913 @default.
• W2051219658 hasConceptScore W2051219658C2776645727 @default.
• W2051219658 hasConceptScore W2051219658C2777953023 @default.
• W2051219658 hasConceptScore W2051219658C2780996683 @default.
• W2051219658 hasConceptScore W2051219658C42219234 @default.
• W2051219658 hasConceptScore W2051219658C71924100 @default.
• W2051219658 hasConceptScore W2051219658C84393581 @default.
• W2051219658 hasConceptScore W2051219658C98274493 @default.
• W2051219658 hasIssue "3" @default.
• W2051219658 hasLocation W20512196581 @default.
• W2051219658 hasLocation W20512196582 @default.
• W2051219658 hasLocation W20512196583 @default.
• W2051219658 hasLocation W20512196584 @default.
• W2051219658 hasOpenAccess W2051219658 @default.

• next